C difficile risk
Oral Bioavailability
IV-$6/d PO-$0.35/d


Defined criteria for use and/or important safety considerations. See below for more information.

IVPO500 mg IV q24h250 - 500 mg PO q24h

General Information

  • Urethritis/cervicitis: Chlamydia and gonorrhea (in combination with 3rd gen cephalosporin)

  • Pertussis

  • Nontuberculous mycobacteria*: prophylaxis (advanced HIV infection) and treatment (in combination with other medications)

  • Bartonella infections

  • Legionella infections


  • Bacterial COPD exacerbation

  • Acute otitis media

  • Bacterial conjunctivitis

  • Mild community acquired pneumonia

  • Pelvic inflammatory disease (in combination)

  • Salmonella, Shigella, traveler’s diarrhea

  • Cesarean section (non-elective) prophylaxis

Should not be used as monotherapy in individuals with nontuberculous mycobacteria

  • Prolonged QTc interval and Torsades de Pointes

  • Potential for drug-drug interactions

  • Prolongation of QTc interval: association with increased risk of sudden cardiac death

  • Diarrhea (5%)

  • Rare cytopenias

  • Increased liver enzymes

Prolonged half life may contribute to macrolide resistance

  • Other drugs that prolong QTc

  • Increases cyclosporine levels

  • May increase digoxin levels

  • Statins increased risk of rhabdomyolysis

Antimicrobial class: Macrolide

Pregnancy category: B

Average serum half life: 68 hours

Biliary penetration: Therapeutic

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Poor

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.